Marianne van der Steen is Professor of Entrepreneurship in Healthcare at the Technology-inspired Institute of Regenerative Medicine (MERLN), Faculty of Health, Medicine and Life Sciences, Maastricht University. She has been appointed director of RegMed XB and member of the board of governors of RegMed XB foundation. Marianne van der Steen received her PhD degree in 1999 from Twente University. Her research focus is on biomedical entrepreneurship, specifically on the scaling-up of ventures. At MERLN, she is responsible for biomedical entrepreneurship valorization, training and education from the lab to a spin-off company.
In addition, she is the founding director of executive life sciences entrepreneurship programs such as the Global Investor Forum, the Global Scale-up Program and the executive Master MBI Life Sciences & Health (currently member of the advisory board). Since 2006, she has been involved in life sciences start-ups, served in early stage start-up investor boards and national and international advisory boards related to entrepreneurship and valorization in the Netherlands, Belgium and the United States.
Vanessa LaPointe is the Scientific Coordinator of RegMed XB. She is also in the tenure track as an Assistant Professor in the MERLN Institute for Technology-Inspired Regenerative Medicine. She first trained as a biomedical engineer at The Johns Hopkins University (USA), but moved into the field of tissue engineering and regenerative medicine during her PhD with Prof. Molly Stevens at Imperial College London. Currently, her group works at the interface of materials science and stem cell biology to better understand how biomaterials can influence cell fate.
Tom Mastenbroek is the Project Manager for RegMedXB. He studied biology at the University of Wageningen and during his master’s education he specialized in cellular differentiation and immunology. In 2016, he obtained his Ph.D. in the field of vascular biology, vessel wall remodelling and thrombosis & haemostasis at Maastricht University under the guidance of Dr. Judith Cosemans and Prof. Johan Heemskerk. In his thesis, he showed for the first time the potential of blood platelets to degrade extracellular matrix and the involvement of platelets in pathological remodelling of the vessel wall after an atherothrombotic event. This concept was further exploited during his PostDoc where he identified novel ways of inhibiting platelet dependent growth factor secretion aiming to block pathological vascular remodelling.
Since 2009 Marcel Hammink has helped dozens of large organizations to optimize their communication with the press and the public. To that effect his company Marcel Hammink Media provides all kinds of goods and services: mediatraining and -advice, films and books. Amongst his customers are: the ministries of defense and justice, RIVM, Trimbos, Eneco, Menzis, TenneT, Universities of Twente and Maastricht, UMCG, Roessingh, Health Valley.
Marcel studied public administration, international relations and journalism (postdoc). He worked as a journalist for 15 years. From 2000-2009 he was senior tv-reporter of Nieuwsuur, the leading current affairs program of Dutch public television, NPO-2. In 2007 he won the RD-Persprijs.
Dr. Mike Shaw is leading the valorisation efforts for RegMedXB. He also heads up the Leiden Regenerative Medicine Platform, which spearheads the LUMC’s commercialisation work in this field. Mike has a background in small molecule drug discovery, having trained in the UK and US as a Medicinal Chemist, before joining the major Belgian biotech UCB, where he worked on two discovery projects which successfully entered the clinic. He then brought his industrial experience back to an academic environment at the LUMC, where he coordinated valorisation in the hospital’s research division for two years before taking up his current roles.
Jeanine is a driven and creative entrepreneur, analytical and determined. She is has experience and expertise in business and product development of high tech applications in regenerative medicine, medical devices and food. Jeanine cofounded 2 companies and brought 5 products to the market. In the process of realizing this, she took up CTO/CEO roles building and coaching startup R&D and manufacturing teams, setting up operations and raised funding to realize the companies goals. She has a broad network in the relevant fields with investors, business partners, medical and scientific professionals, notified bodies, regulatory affairs specialist, governmental organizations and intellectual property lawyers.
Romina Gentier studied Biomedical Sciences at the University of Hasselt. In 2008, she received her bachelor’s degree and in the same year she started her master in Clinical and Molecular Life Sciences. In 2010, she graduated and received her master’s degree with the mention great honors. Subsequently, she started her PhD project at School for Mental Health and Neuroscience (MHeNS) Maastricht University with Dr. Fred van Leeuwen as co-promotor and Prof. Dr. Harry Steinbusch and Prof. Dr. David Hopkins as promotors. In November 2015 she received her PhD degree for her research entitled ‘’UBB+1 an important switch in the onset of Alzheimer’s disease’’. Since November 2015 Romina works as project manager and management assistant in the CTR group of MERLN. In addition, she started working recently within RegMed XB.